Advancing the systematic implementation of patient experience data in healthcare decision-making: multi-stakeholder insights on barriers, opportunities and policy ways forward Authors: Alice Vanneste, Io Wens, Peter Sinnaeve, Tom Adriaenssens, Isabelle Huys Published: 2026 ABSTRACT BackgroundPatient experience data (PED), including patient-reported outcomes (PROs), patient-reported experiences (PREs), patient preferences (PPs), and patient input, are instrumental to better understand patients’ perspectives and inform decision-making. Healthcare decision-makers increasingly recognize the value of PED, but challenges impede its implementation in practice. This qualitative study aims to identify stakeholders’ insights on these barriers, as well as opportunities and concrete policy ways forward for systematically implementing PED in healthcare decision-making.MethodsSemistructured interviews (n = 38) were conducted with stakeholders from healthcare industry, academia, non-profit organizations, regulatory authorities, pricing and reimbursement (P&R) agencies, and patient organizations across Europe. The interviews were transcribed ad verbatim and analysed qualitatively using thematic framework analysis.ResultsStakeholders raised several barriers impeding the integration of PED in healthcare decision-making: (1) lack of clear European policy frameworks and guidance on standardized requirements and quality criteria for collecting and evaluating PED, particularly concerning the design and implementation of PP studies, (2) lack of validated methods and tools for collecting high-quality PED, such as validated PRO measures, and (3) limited knowledge and transparency on the assessment of PED in regulatory and P&R decision-making. Stakeholders emphasized the importance of providing training on effective patient involvement and more research on validated methods and fit-for-purpose tools. Stakeholders emphasized the importance of fostering collaboration and open dialogue among all stakeholders. Developing guidelines and a comprehensive policy strategy that clearly delineates expectations and responsibilities for each stakeholder group was seen as an important way forward.ConclusionsThis policy- and practice-oriented qualitative study identified concrete ways to advance the systematic use of PED in healthcare decision-making. Suggested actions include developing validated and standardized methods and tools, co-created and flexible guidelines and a clear European policy framework delineating expectations and responsibilities. While there was broad alignment on the direction forward, views diverged on who should take the lead in initiating these efforts, underscoring the importance of continued coordination across stakeholder groups.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12961-025-01438-1. Background Healthcare is increasingly recognized as a cornerstone of societal well-being, but persistent gaps remain between the research that is needed and the research that is conducted [1]. To bridge this gap, more targeted research is needed with patients playing a pivotal role in this process. As patients can be considered experts in their disease and treatment outcomes, their insights can help optimize research investments and guide resource allocation more effectively towards disease areas with the highest unmet medical needs [2, 3]. This need for a patient-centred approach has been reinforced by the European Commission in its pharmaceutical strategy report of 2020, which emphasizes that a need-driven and patient-centred policy must be pursued for Europe to maintain its central position in drug research and development [4]. Recognizing patients as key stakeholders and integrating their perspectives into decision-making processes is therefore essential [5]. A common denominator among stakeholders to evolve towards patient-centred healthcare decision-making is the collection, use and implementation of patient-derived evidence throughout the entire medical product life cycle (MPLC) [6, 7]. Patient-derived evidence, often referred to under the umbrella term patient experience data (PED), includes a range of data obtained from patients such as patient-reported outcomes (PROs), patient-reported experiences (PREs), patient input and patient preferences (PP) [8]. These data provide valuable insights into patients’ lived experiences with specific conditions, including their perceptions on disease burden, treatment expectations and preferred outcomes [9]. Various methodologies and tools have been developed to collect PED, including qualitative and quantitative methods [8]. Despite growing recognition of the added value of PED in decision-making, uncertainty among stakeholders on how to operationalize PED effectively limits its implementation in practice [10, 11]. The lack of systematic inclusion in drug development, regulatory evaluations, health technology assessments (HTA) and pricing and reimbursement (P&R) decisions reflects broader challenges in aligning pharmaceutical policy with patient-centred approaches [8, 10]. Therefore, a conceptual shift is needed to fully recognize patients as active stakeholders whose lived experiences and insights are integral to enhance clinical trial relevance, improve benefit–risk assessments and support reimbursement decisions by aligning treatments with patients’ unmet medical needs [12]. Understanding the current barriers and hesitancy among stakeholders that hinder the practical implementation of PED, while identifying opportunities and actionable ways forward, is critical. Capturing stakeholders’ perspectives and generating insights to inform policy and practice helps move from recognizing PED’s importance to systematically integrating it into drug development and evaluation. This study aims to elicit multi-stakeholder perspectives on PED in decision-making. It seeks to determine key stakeholder-perceived barriers and opportunities for systematically implementing PED in the MPLC, as well as identify targeted policy initiatives and recommendations that stakeholders consider necessary to enhance the role of PED in decision-making. By addressing these objectives, this research aims to contribute to ongoing European Union (EU) policy discussions and inform strategies for embedding patients’ perspectives more systematically into healthcare decision-making. Increasing the implementation of PED has the potential to enhance how medical interventions reflect patients’ needs, experiences and preferences, ultimately leading towards a more needs-driven, patient-centred healthcare system. Methods Participant recruitment Experts from diverse stakeholder groups were invited to participate in exploratory interviews, including (1) researchers and developers, (2) decision-makers from regulatory authorities and P&R agencies and (3) patients from patient organizations. Participants were recruited through international and national organizations, literature searches and the research group’s network to allow a heterogeneous and balanced sample. Purposive sampling ensured that selected participants were eligible to provide relevant input regarding the study’s objectives [13]. Selected participants were contacted via email invitation to inform them about the study details. Prior to participation, participants were asked to sign the informed consent form. Conduct of semistructured interviews A semistructured interview approach was adopted, using an interview guide (Supplementary Material 1) with predetermined questions that gave direction while allowing for flexibility and deviation depending on the participant’s knowledge and conversation flow. The guide was developed on the basis of a structured scientific literature review and confirmed through pilot interviews conducted for each stakeholder group. Insights from these pilots were included in the final analysis. Interviews, lasting approximately 1 h, were conducted between March and June 2023, either online or in person, depending on the participant’s preference. Two researchers (A.V. and I.W.) conducted the interviews until data saturation was reached, defined as the point at which no new information or themes emerged in the data [14]. Interviews were held in English or Dutch and were audio and video recorded via Microsoft Teams for further analysis. Analysis of semistructured interviews The recordings were transcribed ad verbatim and pseudonymized to remove identifying information. The transcripts were analysed qualitatively using NVivo software (release 15.0.0) following thematic framework analysis as described by Lacey et al. [15]. This deductive–inductive approach allowed for coding the data within a predefined analytical framework while leaving room for adaptations based on emerging themes. Two researchers (A.V. and I.W.) independently developed the coding structure, reaching consensus on the final coding based on discussion (Supplementary Material 2). The framework matrix was subsequently developed and charted by one researcher (A.V.), with qualitative interpretations reviewed and discussed among the research team to ensure accuracy and rigour. Findings were synthesized by the research team on the basis of recurring themes, frequency of mention and emphasis observed during the interviews. Statements reflect either individual stakeholder perspectives, identified by participant codes, or aggregated insights derived from patterns across interviews. The results were reported according to the consolidated criteria for reporting qualitative research (COREQ) checklist to ensure rigorous reporting (Supplementary Material 3) [16]. Patient and public involvement Patients or the public were not involved in the study design, conduct or evaluation. However, patient perspectives were integrated through interviews, as they were one of the stakeholder groups included. Ethical approval confirmed that the study design was appropriate and respectful to patient interests. Patients will be involved in the dissemination of findings to promote accessibility and impact. Results Participants’ characteristics A total of 38 interviews were conducted with 39 interviewees to reach data saturation within each stakeholder group (Fig. 1).Fig. 1Stakeholder interviews (n = 38 with 39 interviewees as the industry IND3/4 interview in the subcategory pharmaceutical umbrella organization consisted of two interviewees). EU, European Union; HTA, health technology assessment; P&R, pricing and reimbursement; SME, small and medium-sized enterprises Stakeholder interviews (n = 38 with 39 interviewees as the industry IND3/4 interview in the subcategory pharmaceutical umbrella organization consisted of two interviewees). EU, European Union; HTA, health technology assessment; P&R, pricing and reimbursement; SME, small and medium-sized enterprises Current landscape of PED: definition, perceived value and use Stakeholders were generally familiar with the term PED but noted that different terminologies are used across contexts. Industry stakeholders tended to refer to the US Food and Drug Administration (FDA) definition, while European regulators focused on the European Medicines Agency (EMA) definition. Across the MPLC, stakeholders highlighted the value of PED to inform decision-making by better understanding patients’ full care journey, including their unmet needs, lived experiences and treatment priorities. In drug development, PED was seen as useful for shaping research agendas and questions, defining meaningful outcomes and optimizing clinical trial designs. In drug assessment, it helped contextualizing decisions by focusing on what matters (most) to patients. Among PED types, PROs were most frequently mentioned and perceived as well-established, especially in oncology. Stakeholders also referred to patient input (for example, during advisory meetings or committees), either from naive patients sharing personal experiences or patient representatives providing broader community perspectives. PP and PREs were less discussed and used by stakeholders. Stakeholder-perceived barriers hampering the implementation of PED Barriers related to PED collection While stakeholders generally recognized the value of PED, views diverged on its relevance across disease areas. Many emphasized its importance in areas with high unmet needs, major quality of life impact or limited clinical trial data, such as rare diseases or treatments with marginal efficacy but patient-centred benefits (for example, lower burden of treatment). Conversely, PED was considered less relevant in well-established, asymptomatic or highly regulated conditions or treatments with well-defined benefit–risk profiles or minor changes (for example, dose adjustments). Others cautioned that this selective approach risks fragmentation and argued for more systematic collection across all disease areas. Despite these differences, all stakeholders warned against the tokenistic use of PED, where PED is collected as tick-box exercises to meet formal requirements rather than inform decision-making. Most stakeholders therefore opposed mandatory PED collection and instead favoured a structured yet flexible approach where the relevance of PED should be systematically considered case-by-case with justification when omitted: “Meaningful patient involvement also means to accept that sometimes you do not need it” (patient PTN8). Furthermore, stakeholders emphasized the challenge of selecting appropriate methods for collecting robust, high-quality PED. They reflected on several methodological considerations, such as limited sample representativeness and generalizability, lack of validated and fit-for-purpose methods, tension between generic and disease-specific measures, risk of patient overburden and barriers to data sharing and reuse (Table 1). Table 1Methodological considerations related to PED collection raised by stakeholdersMethodological considerationsStakeholders’ explanationLimited sample representativeness and generalizabilityMany stakeholders warned against bias from overrepresenting highly educated, (digitally) literate and engaged patients, while underrepresenting minority groups and less visible subpopulations, particularly in rare diseases. Much of patients’ experiences are driven by their individual healthcare context and therefore, many aspects cannot be generalized. While international data offer broader insights, several expressed the need for national data to contextualize local decision-makingLack of validated and fit-for-purpose methodsStakeholders highlighted the lack of scientifically robust, reliable and sensitive tools for collecting high-quality PED and the need for consensus and guidance on how and when to use them: “Just as there are scientific criteria for good clinical practice and randomized clinical trials to ensure rigorous evidence, there should also be such standards for PED” (industry IND12). Regulators emphasized the importance of using validated methods that capture outcomes meaningful to patients. Several stakeholders advocated for standardizing existing tools, while others called for developing new onesTension between generic and disease-specific measuresWhile stakeholders indicated that generic tools (for example, EQ-5D) support comparability across diseases, with P&R stakeholders indicating its common use in economic evaluations, disease-specific measures can provide greater sensitivity to disease-relevant nuances. Many indicated the need for a combined approach to balance comparability with relevanceRisk of patient overburdenDespite high willingness to participate, patient stakeholders warned against involving the same individuals, especially those with severe illnesses. Repetitive requests without visible impact may lead to fatigue and dropoutBarriers to data sharing and reuseImplementation of PED is also hampered by reluctance or inability to share and reuse data, particularly within industry. Barriers include fragmented data structures, unclear ownership and concerns about commercial misuse Table 1Methodological considerations related to PED collection raised by stakeholdersMethodological considerationsStakeholders’ explanationLimited sample representativeness and generalizabilityMany stakeholders warned against bias from overrepresenting highly educated, (digitally) literate and engaged patients, while underrepresenting minority groups and less visible subpopulations, particularly in rare diseases. Much of patients’ experiences are driven by their individual healthcare context and therefore, many aspects cannot be generalized. While international data offer broader insights, several expressed the need for national data to contextualize local decision-makingLack of validated and fit-for-purpose methodsStakeholders highlighted the lack of scientifically robust, reliable and sensitive tools for collecting high-quality PED and the need for consensus and guidance on how and when to use them: “Just as there are scientific criteria for good clinical practice and randomized clinical trials to ensure rigorous evidence, there should also be such standards for PED” (industry IND12). Regulators emphasized the importance of using validated methods that capture outcomes meaningful to patients. Several stakeholders advocated for standardizing existing tools, while others called for developing new onesTension between generic and disease-specific measuresWhile stakeholders indicated that generic tools (for example, EQ-5D) support comparability across diseases, with P&R stakeholders indicating its common use in economic evaluations, disease-specific measures can provide greater sensitivity to disease-relevant nuances. Many indicated the need for a combined approach to balance comparability with relevanceRisk of patient overburdenDespite high willingness to participate, patient stakeholders warned against involving the same individuals, especially those with severe illnesses. Repetitive requests without visible impact may lead to fatigue and dropoutBarriers to data sharing and reuseImplementation of PED is also hampered by reluctance or inability to share and reuse data, particularly within industry. Barriers include fragmented data structures, unclear ownership and concerns about commercial misuse Methodological considerations related to PED collection raised by stakeholders Resource and funding constraints were another key barrier, with various stakeholders highlighting issues related to time, funding and trained staff needed to collect, analyse and integrate PED effectively. Some industry stakeholders noted that early PED collection activities are often deprioritized owing to time pressure, lack of infrastructure and limited access to patient groups across all disease areas. Patient representatives also emphasized the need for financial compensation to support participation as it can be energy-consuming and costly. Additional less frequently discussed barriers included concerns about selective PED use to support favourable outcomes and pricing, ethical questions around financial incentives, confidentiality issues, language barriers due to complex terminology and English as default language and limited access to information and entry points for patients. Barriers related to PED assessment Stakeholders noted the limited availability of high-quality PED before assessment as a barrier. PED is often not submitted (partly owing to the absence of a defined space for such data), and when available, it may be poorly reported or lack methodological transparency, which can lead to trust issues, especially when collected by industry or nonindependent sources. Assessors often lack experience and knowledge needed to interpret PED, particularly outcomes of PP studies, not only because few PED submissions are available but also because PED interpretation is not yet embedded in their competence profiles and there is little alignment on its use within assessments. This results in hesitancy and reluctance among assessors due to their unfamiliarity with its use: “It’s a chicken-and-egg situation: regulators say that we’re not providing the quality of data they need, but they haven’t given us much guidance on what that quality should look like” (Industry IND10). This tension is compounded by resource and funding constraints, especially within regulatory bodies facing competing priorities. During assessment, PED’s perceived subjectivity was often discussed by stakeholders as a challenge. While stakeholders acknowledged its subjective nature, they stressed that rigorous and systematic collection using validated methods can yield robust and representative data. Furthermore, stakeholders’ perspectives differed concerning the weighing of PED against clinical trial evidence. Several supported equal weighting when PED is robust and population-based, while for others, clinical trial data remained essential to demonstrate safety and efficacy. P&R stakeholders also raised that additional trade-offs emerge between clinical, economic and patient aspects, often constrained by budget impact and affordability. Most saw PED and clinical trial data as complementary, with PED serving as a so-called filter to ensure clinical outcomes align with what matters to patients: “The clinical trial data is the world in black and white. By adding PED, it becomes a moving image in colour” (PTN2). After assessment, a lack of transparency was seen as a key barrier. Mainly industry stakeholders felt uncertain about whether and how PED was considered and used in decision-making. The absence of clear methodological standards, submission expectations or structured reporting on the use of PED and its impact in assessments leaves PED as a so-called black box, making it difficult to justify internal investment. This lack of clarity also limits patient and public understanding of access and resource allocation decisions. Finally, limited harmonization across countries with inconsistent expectations and assessment practices further complicates consistent PED integration. Opportunities for systematic PED implementation in practice Opportunities related to PED collection A key opportunity mentioned was strengthening methodological standards and quality criteria to enhance the reliability, credibility and usability of PED. Regulators and P&R stakeholders emphasized the need for the validation of tools, qualification of new methods, meaningful thresholds and core outcome sets with overviews of available state-of-the-art methods, including qualitative research. Patient stakeholders emphasized purposeful use of methods and suggested artificial intelligence could improve data quality. Stakeholders also called for increased public funding and resources through national and European initiatives to enable independent PED collection. Building capacity among patient organizations, especially disease-specific and European-wide groups, requires resources, sustainable structures and professional staff. Several also stressed the importance of cluster or umbrella organizations to cover rare and related conditions. To reduce variability in PED collection, several stakeholders emphasized the importance of establishing clear frameworks and long-term investments that ensure patient involvement is credible and unbiased, especially given concerns about industry-driven funding. Mainly patient stakeholders stressed the need for two-way communication on when and how they can be involved, including feedback on their influence, to build trust: “If you want patients to participate and share their experiences, you need to give them something back, otherwise they get frustrated and disengage” (PTN7). Finally, stakeholders often emphasized that improving PED collection requires coordinated efforts with distinct roles and responsibilities across stakeholder groups (Table 2). Table 2Distinct roles and responsibilities across stakeholder groups related to PED collectionStakeholder groupsRoles and responsibilitiesResearchers, academics and cliniciansResearchers and academics with appropriate expertise are needed to ensure methodological robustness and scientific neutrality, supported by clinicians who have direct contact and interactions with patients and can, for example, facilitate recruitmentIndustryParticipants emphasized transparent PED collection and reporting by healthcare developers, which includes to clearly describe the methods used, disclose relationships with patient organizations and follow guidelines to ensure high-quality PED: “The industry should be perhaps in the driving seat, but there will be a need for transparency.” (pricing and reimbursement agency P&R3). In some cases, this may require cultural change, cross-company alignment and modified processes within companiesPatient organizationsPatient organizations play a critical role as they can proactively advocate their community needs, collect their own patient-derived data to support decision-making and facilitate access to knowledgeable and motivated patient representatives to involve as partnersRegulators and P&R assessorsWhile EMA’s 2025 strategy already send a clear message, stakeholders indicated that clearer expectations for PED research would be beneficial and specific guidance is needed on what types of PED are valued, when and how such data should be collected. Clarity and consistency would provide a strong incentive for meaningful PED collection across stakeholder groups Table 2Distinct roles and responsibilities across stakeholder groups related to PED collectionStakeholder groupsRoles and responsibilitiesResearchers, academics and cliniciansResearchers and academics with appropriate expertise are needed to ensure methodological robustness and scientific neutrality, supported by clinicians who have direct contact and interactions with patients and can, for example, facilitate recruitmentIndustryParticipants emphasized transparent PED collection and reporting by healthcare developers, which includes to clearly describe the methods used, disclose relationships with patient organizations and follow guidelines to ensure high-quality PED: “The industry should be perhaps in the driving seat, but there will be a need for transparency.” (pricing and reimbursement agency P&R3). In some cases, this may require cultural change, cross-company alignment and modified processes within companiesPatient organizationsPatient organizations play a critical role as they can proactively advocate their community needs, collect their own patient-derived data to support decision-making and facilitate access to knowledgeable and motivated patient representatives to involve as partnersRegulators and P&R assessorsWhile EMA’s 2025 strategy already send a clear message, stakeholders indicated that clearer expectations for PED research would be beneficial and specific guidance is needed on what types of PED are valued, when and how such data should be collected. Clarity and consistency would provide a strong incentive for meaningful PED collection across stakeholder groups Distinct roles and responsibilities across stakeholder groups related to PED collection Opportunities related to PED assessment Stakeholders stressed the importance of transparency on how PED is considered and used during assessments to manage expectations and clarify its role. In P&R processes, national guidance was requested to help reduce uncertainty, streamline data collection and support the use of PED in access decisions. Including patient representatives in appraisal committees was viewed by several stakeholders as a way to broaden the vision: “Patient representatives within the commission will be able to stress some patient-relevant aspects that maybe we will not have seen before” (pricing and reimbursement agency P&R3). To ensure PED is systematically considered, stakeholders proposed templates or dedicated PED reporting sections in submissions. They stressed the need for flexibility in reporting, warning against both overly rigid and overly permissive frameworks: “If the framework is too rigid, it won’t work as it becomes a tick-box exercise. If it’s too loose, you won’t have enough input and it won’t work either” (PTN8). Stakeholders also supported public reporting of PED use to understand how it was assessed and contributed to the decision-making. Mainly industry and regulators endorsed including PED in European Public Assessment Reports (EPARs). While EPARs are less accessible to patients, they offer value to physicians and future applicants to further build on. Stakeholders were more cautious regarding the inclusion of PED in the summary of product characteristics (SmPC) or product label. Mainly industry saw potential benefits for informing prescribers and supporting marketing efforts. Others warned against promotional risks and limited patient relevance. Including PED in P&R documents was also suggested to help patients understand how PED shaped access decisions. Training and education Most stakeholders highlighted that training and education are essential for broadening patient involvement beyond the usual patient experts. Participants highlighted the need for training for developers gain expertise in designing and interpreting PED, including qualitative and quantitative research skills, as well as practical aspects such as reimbursement, privacy, planning and relationship-building, to ensure PED is collected and used rigorously. Stakeholders further emphasized the value of training assessors to build knowledge, expertise and confidence in evaluating PED, with workshops and case studies suggested as helpful tools. Training for patients and patient organizations was also strongly emphasized. Equipping them with knowledge of the drug development process, healthcare system and PED terminology helps ensure meaningful contribution and effective communication, especially in generalizing personal experiences into broader patient perspectives. Policy actions and ways forward Guidelines Stakeholders most frequently highlighted the need for co-created guidelines with clear recommendations, concrete expectations and minimum requirements to support consistent yet feasible and adaptable PED implementation. Stakeholders cautioned against overly prescriptive or rigid approaches that might stifle innovation: “There is a difficult balance that needs to be struck between giving Based on the authors' synthesis of recurring themes and emphasis observed across stakeholder interviews, three areas were identified as particularly relevant for guideline development content: (1) PED collection, (2) PED assessment and (3) patient involvement and engagement (Table 3). Table 3Main content for PED-related guidelinesGuideline areaContentPED collectionPractical guidance on: (1) clear definitions with glossary to standardize PED-related terminology, (2) good practices on how, when and in which context to collect PED, with clear instructions on what data are needed, how it should be collected, for what purpose and what impact it has, (3) greater alignment on existing and available methods and tools to provide methodological standards and general principles to generate high-quality PED and (4) frameworks for qualifying and validating novel methods, such as new PRO measuresPED assessmentGuidance by assessors on: (1) how PED is included and used in their decision-making, specifying when and what different types of data are accepted to support which decisions and (2) how PED should be reported and included in documents, such as the clinical trial dossierPatient involvement and engagementGuidance on: (1) the value and importance of PED and involving patients directly by indicating the benefits and (2) who, when, where and how to involve and engage patients in all stages across the MPLC, with practical advice on selecting and compensating participants and integrating their input. Existing initiatives (for example, EUPATI, PARADIGM, PFMD) and checklists (for example, GRIPP) can serve as useful foundations Table 3Main content for PED-related guidelinesGuideline areaContentPED collectionPractical guidance on: (1) clear definitions with glossary to standardize PED-related terminology, (2) good practices on how, when and in which context to collect PED, with clear instructions on what data are needed, how it should be collected, for what purpose and what impact it has, (3) greater alignment on existing and available methods and tools to provide methodological standards and general principles to generate high-quality PED and (4) frameworks for qualifying and validating novel methods, such as new PRO measuresPED assessmentGuidance by assessors on: (1) how PED is included and used in their decision-making, specifying when and what different types of data are accepted to support which decisions and (2) how PED should be reported and included in documents, such as the clinical trial dossierPatient involvement and engagementGuidance on: (1) the value and importance of PED and involving patients directly by indicating the benefits and (2) who, when, where and how to involve and engage patients in all stages across the MPLC, with practical advice on selecting and compensating participants and integrating their input. Existing initiatives (for example, EUPATI, PARADIGM, PFMD) and checklists (for example, GRIPP) can serve as useful foundations Main content for PED-related guidelines Several stakeholders suggested that guideline development could follow, consensus-based process led by regulators and involving all stakeholder groups. A tiered approach was preferred, starting with a general, nonmandatory framework with core principles expanded over time with more specific, modular guidance tailored to specific contexts. While mainly industry cautioned against one-size-fits-all guidelines, regulators emphasized the need to gain more experience before formalizing guidance: “It is not possible without knowing the possibilities. It would be guesswork and easily accused of putting too few things forward or being too liberal” (regulator RGL4). For most stakeholders, ongoing evaluation is essential to help them understand what works, how the guidance is applied in practice and what further adjustments or additions may be needed. Stakeholders also called for international guidance (for example, at ICH level) to align international efforts and global assessment standards. Given long timelines, many supported interim European actions, such as the EMA reflection paper or national-level initiatives that reflect local contexts. Several noted that nonbinding guidance may have limited impact, suggesting stronger legislative support and the EU HTA regulation providing a timely opportunity to embed PED into joint assessments and influence national decision-making. Case studies and good practices Beyond formal guidance, stakeholders viewed case studies and good practices as key to advance PED implementation. Well-developed pilots and case studies were considered to be able to demonstrate how PED was applied and informed decision-making, with successful experiences and challenges helping to clarify its added value and issues. Stakeholders also stressed the need for visibility of diverse cases and their evaluation to support learning and promote more consistent use in practice. Cross-country learnings Stakeholders emphasized the value of cross-country learnings, adapted to national contexts, to advance meaningful and pragmatic PED implementation. The US FDA was frequently mentioned by industry and regulators as a global frontrunner, with their legally embedded patient-focused drug development (PFDD) guidelines shaped by public consultations and including standardized templates and disease-specific patient listening sessions. However, several cautioned its overly engineered approach may be too rigid for Europe owing to structural and cultural differences. The UK (National Institute for Health and Care Excellence, NICE) was also highlighted for embedding PED into HTA processes via guidelines on patient involvement, citizen councils and transparent reporting. Canada was recognized for its long-standing frameworks, while the Netherlands and France were noted for, respectively, their national consultations with government-supported patient organizations using structured questionnaires and publicly available decision rationales. Multi-stakeholder interactions Most stakeholders mentioned that PED integration is a shared responsibility requiring a collaborative, multi-stakeholder approach with early and ongoing interaction between regulators, HTA and P&R bodies, industry, clinicians, patients and other experts. Workshops such as EMA’s PED workshop were valued for sharing perspectives, fostering mutual understanding and identify practical steps forward. Collaborative projects and consortia were seen useful for co-creating methods and frameworks. Early scientific advice was highlighted as a key opportunity to tailor PED integration to specific products: “Drug development is so specific to each individual drug, so I am not sure if guidance will be able to provide advice for each as scientific advice can” (RGL1). While not mandatory, stakeholders mentioned that these discussions could help align expectations and strengthen PED quality. Several stakeholders additionally suggested involving patients in early scientific advice meetings to guide discussions on PED. Including PED in advice templates was also suggested to ensure consistent early consideration. Discussion This study provides actionable insights into advancing the systematic use of PED in healthcare decision-making. By exploring perspectives across diverse stakeholder groups, the study identifies practical, methodological and policy dimensions complicating PED’s collection and assessment in decision-making, as well as concrete ways forward and practical directions. While there was broad alignment on the direction forward, diverging views emerged on certain aspects, highlighting the need for coordination and collaborative efforts across stakeholder groups. As summarized in Fig. 2, stakeholders highlighted various barriers that currently limit the effective collection of PED in practice, including methodological considerations, inconsistent implementation across disease areas, practical constraints, as well as barriers before, during and after assessment such as lack of experience and knowledge, subjectivity of PED and lack of transparency on how PED is assessed and used. Despite these barriers, stakeholders discussed concrete opportunities and policy ways forward. Stakeholders frequently identified promising avenues such as clear but flexible guidelines, case studies and good practices to share experiences, methodological standards and quality criteria for validated, fit-for-purpose tools and more multi-stakeholder interactions, particularly through early scientific advice. However, diverging opinions emerged concerning who should initiate the first actions. While industry called for regulatory guidelines to facilitate PED collection, regulators preferred gaining more experience in assessing PED before drafting such guidelines. To reconcile these differences, stakeholders across groups frequently emphasized the importance of fostering collaboration and open dialogue. Developing a pragmatic yet ambitious policy strategy that clearly delineates expectations and responsibilities was considered by stakeholders as important to enable continuous learning and implementation across the MPLC.Fig. 2Stakeholder-perceived barriers, opportunities and policy ways forward for PED collection and assessment. PED, Patient experience data collection; PED, Patient experience data assessment Stakeholder-perceived barriers, opportunities and policy ways forward for PED collection and assessment. PED, Patient experience data collection; PED, Patient experience data assessment Our findings align with and expand upon existing literature on PED integration into healthcare decision-making. Identified methodological challenges and practical barriers, such as the lack of validated tools and consensus on appropriate methods, aligns with concerns highlighted in prior research. For instance, a literature review by van Overbeeke et al. (2019) emphasized the need for robust and consistent approaches to ensure the reliability and validity of PP studies [17]. Similarly, Almeida et al. (2024) stressed the lack of standardized methodologies and harmonization, which hampers the systematic inclusion of PED in regulatory, market access and clinical decisions [12]. The diversity of perspectives among stakeholders in our study underscored the complexity of the challenges, highlighting the need for multi-stakeholder dialogue to facilitate the systematic implementation. This shift is emphasized by Schroeder et al. (2022), calling for multi-stakeholder efforts with more aligned approaches to overcome fragmentation and the lack of integration of current actions [18]. International efforts such as the co-creation of the Global Patient Experience Data Navigator by Patient Focused Medicines Development, as detailed by Willgoss et al. (2023), exemplifies a collaborative initiative that reflects the multi-stakeholder and collaborative approaches high lighted by participants in this study [19, 20]. Collectively, existing literature suggests growing international momentum for PED integration. Bertelsen et al. (2023) describes this expending landscape with emerging initiatives evolving from general openness towards structured guidance in regulatory and HTA processes [21]. However, gaps remain in practical implementation and alignment across stakeholders, concerns that this study corroborate. As PED implementation is still evolving, clear policy strategies and collaborative actions as outlined in this study will be imperative to facilitate the systematic implementation of PED in decision-making. Positioning and future directions The evolving landscape of patient-centred care is increasingly recognized as the approach needed in healthcare, resulting in a paradigm shift towards the collection, assessment and implementation of PED in several decision-making contexts. The European Patients’ Forum (2024) underscores the importance of incorporating PED to enhance patient access and achieve better health outcomes, advocating for its inclusion in marketing authorization applications to ensure that medicines meet patients’ needs and preferences [22]. These views align with broader regulatory shifts, such as the EMA’s Regulatory Science Strategy to 2025 and the proposed reform of the EU’s Pharmaceutical Legislation of 2023 focusing on amplifying patients’ voices in regulatory decision-making with more new medicines addressing unmet medical needs and increased patient representation in assessment committees [23, 24]. This patient-centric vision builds on EMA’s workshop in 2022 on PED [25]. In the USA, the FDA’s advancements under its PFDD initiative provided practical tools that further underscore how regulators can formalize the use of PED [26]. At the HTA level, the EU HTA Regulation of 2025 provides another avenue for enhanced PED implementation, supported by EUnetHTA’s framework for transparently including input from patients as external experts [27]. Despite these efforts, our study suggests that stakeholders call for further progress with more flexible, tiered guidance. The forthcoming ICH guideline and recently published EMA’s reflection paper offer a first step to address this need, supported by early scientific advice for practical, in-depth discussions [28]. Clearer roles and responsibilities could further encourage developers to collect high-quality, relevant PED aligned with assessors’ expectations. To facilitate uptake and good practices, transparent reporting of PED in assessment documents could create closed feedback loops that foster continuous learning and harmonization, accelerated by international collaborations and cross-country learnings to share good practices and case studies. These timely, practice-oriented actions could advance iteratively towards a more patient-centred healthcare system that systematically implements PED at each stage of decision-making along the MPLC. Strengths and limitations Semistructured interviews provided in-depth yet nuanced insights from a diverse and inclusive stakeholder sample, allowing to identify alignment and divergence across perspectives on this complex landscape of patient-centred healthcare. The findings offer pragmatic directions and actionable considerations informed by multi-stakeholder perspectives, providing a basis for developing practical and implemented strategies that could be adapted to local contexts. While the study provides rich insights into stakeholder-perceived barriers, opportunities and policy ways forwards, it does not systematically address gaps in scientific literature. As a policy- and practice-oriented qualitative exploration, the findings should be interpreted as reflecting stakeholder perspectives that complement, rather than comprehensively review, the existing evidence on PED implementation. Stakeholder participants were purposefully considered to minimize selection bias, but many were already involved or familiar with PED, potentially skewing the sample towards more informed or favourable PED views. Therefore, the generalizability of the findings should be carefully considered, as insights may not be fully representative of the broader stakeholder group. While interviewers held no vested interest in the study’s outcome, their prior knowledge and assumptions may have influenced the interview direction. Although perspectives sometimes differed across stakeholder groups, the qualitative design and limited subgroup sizes did not allow for a systematic differentiation of findings by stakeholder type. Instead, the analysis focused on identifying overarching themes and shared insights across the stakeholder spectrum. Conclusions This study revealed the critical stakeholder-perceived barriers that challenge the effective and systematic implementation of PED in healthcare decision-making and identified practical ways forward. While stakeholders shared certain priorities such as the need for training on effective patient involvement and transparency on PED assessment, their opinions differed regarding others. The diversity of perspectives among stakeholders underscored the complexity of these challenges and the need for multi-stakeholder dialogue. Suggested actions include validated and standardized methodologies and tools, co-created and flexible guidelines and a clear European policy framework delineating expectations and responsibilities. Fostering critical and constructive reflections on these strategies will be important to overcome current barriers and pave the way towards the collective goal of improving evidence-based, patient-centred healthcare decision-making that meets patients’ needs and preferences. Supplementary Information Additional file 1. Additional file 1.